Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DynaGen

This article was originally published in The Gray Sheet

Executive Summary

Completes Phase I study of its SPT I single-protein tuberculin test and submits application to FDA to begin Phase II studies. Intended for "in vivo use as an aid in diagnosing infection with Mycobacterium Tuberculosis by the standard skin-test procedure," the test's "purity and stability" allow it to "be standardized for quality control purposes," the firm says. DynaGen also believes SPT I "may allow for easier interpretation of skin reactions to TB infection and may produce less of the non-specific reactions characteristic of the current [partially purified protein derivative] test"
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT001659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel